DeepCure

Executive Summary

DeepCure is a Boston-based therapeutics company leveraging a proprietary AI platform that combines physics-based modeling, machine learning, and laboratory automation to discover novel small molecules for previously intractable targets. Founded in 2020, the company has rapidly advanced a pipeline focused on challenging targets with high unmet medical need. Its lead asset is currently in IND-enabling studies, with additional programs targeting oncology, immunology, and neurological disorders. DeepCure's platform aims to reduce the time and cost of drug discovery by generating high-quality candidates with optimized properties. The company is privately held and has not disclosed its total funding or valuation, but its innovative approach positions it as a promising player in the AI-driven drug discovery space. Given its early stage, DeepCure faces typical development risks, including clinical validation and competitive dynamics, but its technology and focus on undrugged targets offer significant upside potential if successful.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Asset70% success
• 2027Platform Partnership with Major Pharma40% success
• H2 2026Series A or B Financing Round80% success